Concepedia

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

B.A. Tjoa, Sheila J. Erickson, Victoria Bowes, Haakon Ragde, Gerald M. Kenny, Oliver E. Cobb, Robert C. Ireton, M.J. Troychak, Alton L. Boynton, G.P. Murphy

The Prostate · 1997 · 127 citations · 9 references

DOIFull text

Open access

Abstract

The responses observed in this phase I clinical trial are significant and of long duration. Most of the responders were in treatment groups infused with DC pulsed with PSM-P1 or -P2, suggesting the requirement of both components for effective immunotherapy.

References

9

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

Catia Traversari, Pierre van der Bruggen, Immanuel F. Luescher et al. · The Journal of Experimental Medicine · 1992 · 694 citations · Full text

, , +20

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

George E. Peoples, Peter S. Goedegebuure, Robert W. Smith et al. · Proceedings of the National Academy of Sciences · 1995 · 440 citations · Full text

, , +20

Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

Donald L. Morton, Leland J. Foshag, Dave S.�B. Hoon et al. · Annals of Surgery · 1992 · 404 citations · Full text

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

G.P. Murphy, B.A. Tjoa, Haakon Ragde et al. · The Prostate · 1996 · 395 citations

Partial purification and some properties of BB7.2 a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28

Peter Parham, Frances M. Brodsky · Human Immunology · 1981 · 320 citations

, , +14